SOURCE: TriMarkPublications.com

TriMarkPublications.com

April 11, 2011 14:08 ET

Cancer Vaccines Market Forecasted to Catapult to Over $7 Billion by 2015

NEW YORK, NY--(Marketwire - Apr 11, 2011) - TriMarkPublications.com cites in its newly published "Cancer Vaccines Markets" report that the cancer vaccines market will catapult to over $7 billion by 2015. For more information, visit: http://www.trimarkpublications.com/products/Cancer-Vaccines-Markets.html.

Cancer vaccines can be divided into six main categories: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. The FDA's first approval of a therapeutic cancer vaccine in 2010 has demonstrated the potential for these novel types of treatments to successfully enter a major market. The cancer vaccines market is driven by the potential for cancer vaccines to be used with existing cancer therapeutics, their possibility of being used as long-term treatments, and their status as niche products fulfilling unmet therapeutic needs.

The "Cancer Vaccines Markets" report covers:

  • Antigen/Adjuvant Vaccines
  • DNA Vaccines
  • Prophylactic Vaccines
  • Therapeutic Vaccines
  • Tumor Cell Vaccines
  • Dendritic Cell (DC) Vaccines
  • Anti-Idiotype Vaccines
  • Cervical Cancer (HPV)
  • Breast Cancer
  • Screening and Cancer Detection
  • Immune Response
  • Personalized Medicine
  • Combination Therapies
  • Pharmaceutical Product Regulation
  • New Drug Application (NDA)
  • Biologics License Application (BLA)
  • Oncology Biomarker Qualification Initiative

The "Cancer Vaccines Markets" report examines companies manufacturing cancer vaccines equipment and supplies in the world. Companies covered include: Advaxis, Agenus (formerly Antigenics), Alphavax, Antigen Express, Apthera, Argos, AVAX, Bavarian Nordic, Bellicum, BioSante, Biovest, Celldex, CG, CureVac, DanDrit, Dendreon, EMD Serono, Geron, Glaxosmithkline, Globeimmune, Immatics, ImmunoCellular, Immunovaccine, Inovio, KAEL-Gemvax, MannKind, Mologen, NewLink Genetics, Northwest, NovaRx, Oxford BioMedica, Prima BioMed, Scancell, Transgene, Trimed, Vaccinogen and Vical.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/products/Cancer-Vaccines-Markets.html.

About TriMarkPublications.com

TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information